We identified 111 patients with MBC and LMD, including patients with the following subtypes: HR+/HER2− (n = 53, 47.7%), HER2+ (n = 30, 27.0%), and triple negative breast cancer (TNBC; n = 28, 25.2%). This evidence concerns the gene HR and triple-negative breast carcinoma.